z-logo
open-access-imgOpen Access
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
Author(s) -
Lazaros Lazaridis,
Elisabeth Bumes,
Dorothee Cäcilia Spille,
Tim Schulz,
Sina Heider,
Sarina Agkatsev,
Teresa Schmidt,
Tobias Blau,
Christoph Oster,
Jonas Feldheim,
Walter Stummer,
Almuth F. Keßler,
Clemens Seidel,
Oliver Grauer,
Peter Hau,
Ulrich Sure,
Kathy Keyvani,
Ulrich Herrlinger,
Christoph Kleinschnitz,
Martin Stuschke,
Ken Herrmann,
Cornelius Deuschl,
Stella Breuer,
Elke Hattingen,
Björn Scheffler,
Sied Kebir,
Martin Glas
Publication year - 2022
Publication title -
neuro-oncology advances
Language(s) - English
Resource type - Journals
ISSN - 2632-2498
DOI - 10.1093/noajnl/vdac137
Subject(s) - temozolomide , medicine , lomustine , oncology , regimen , progression free survival , chemotherapy , clinical trial , surgery , vincristine , cyclophosphamide

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom